FS222
Advanced solid tumors
Key Facts
Indication
Advanced solid tumors
Phase
Phase 1
Status
Active (status post-acquisition)
Company
About F-star Therapeutics
F-star Therapeutics is a UK-based biotech focused on creating next-generation bispecific antibodies for immuno-oncology. Its core achievement is the development of the proprietary Fcab and mAb2 platforms, which generate tetravalent, IgG-like bispecific antibodies designed for enhanced stability, manufacturability, and biological activity. The company's strategy involves advancing its internal pipeline of clinical and preclinical assets while securing strategic partnerships to validate and expand the utility of its modular technology. Following its NASDAQ IPO in 2020, F-star has progressed key assets into clinical trials, positioning itself in the competitive bispecific antibody landscape.
View full company profileTherapeutic Areas
Other Advanced solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |